Overview

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease, infusion reactions, electrolyte abnormalities, and cardiac disorders.
Details
Lead Sponsor:
Takeda
Treatments:
Antibodies, Monoclonal
Panitumumab